Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • UP Govt orders pull...

    UP Govt orders pull back of substandard Atorvastatin medicine from govt hospitals

    Farhat NasimWritten by Farhat Nasim Published On 2019-11-28T14:14:34+05:30  |  Updated On 28 Nov 2019 2:14 PM IST
    UP Govt orders pull back of substandard Atorvastatin medicine from govt hospitals

    The state government, hence, issued an order on November 19 to recall the entire batch of the medicine (Atorvastatin) that was supplied to more than 160 government hospitals and community health centres in the state.


    Lucknow: Taking cognizance of Central Drugs Standard Control Organization (CDSCO) declaring drug samples including a popular cardiac drug, Atorvastatin as Not of Standard Quality (NSQ) in a random test, the Uttar Pradesh State Medical Supplies Corporation has banned the supply of the drug after it failed to pass quality parametres.


    The state government, hence, issued an order on November 19 to recall the entire batch of the medicine that was supplied to more than 160 government hospitals and community health centres in the state.


    This came after samples of Atorvastatin were drawn by the CDSCO North Zone, Ghaziabad officers for conducting the random drug sample test picked from district male hospital Agra. The samples were tested at the Regional Drugs Testing Laboratory (RDTL) Chandigarh and presence of dissolution were found.


    Also Read: CDSCO declares 36 samples of Atorvastatin, Metformin, Paracetamol, others as Not of Standard Quality

    “The assessment report issued by the Chandigarh-based lab said the sample does not conform to the claim as per IP in respect to dissolution and therefore was not found to be of the standard quality, ” reads the official order as quoted by TOI.


    Thereafter, a show-cause notice was issued to the Hyderabad-based supplier firm, Revat Laboratories Pvt. Ltd.


    "A show-cause notice has been issued to the Hyderabad-based supplier firm. Arrangements are being made to provide additional stock to meet the high demand of the medicine, " Health Department spokesperson told IANS.


    The demand for the supply of Atorvastatin is huge as Shyama Prasad Mukherjee Civil Hospital in Lucknow alone needs more than twenty thousand tablets of the medicine per month.

    Atorvastatin, sold under the trade name Lipitor among others, is a statin medication used to prevent cardiovascular disease in those at high risk and treat abnormal lipid levels. It works by reducing the amount of cholesterol made by the liver.

    Also Read: DRL recalls 80,000 plus bottles of Atorvastatin from the US due to quality concerns
    Atorvastatincardiac drugCDSCOCentral Drugs Standard Control OrganizationcholesterolDrug BanDrug Recallgovt hospitalsLipitorrdtl chandigarhRevat LabsState Medical Supplies CorporationstatinUP govtup govt order
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok